Rain or shine, volunteers and supporters gathered in Texarkana, Texas, for the annual Walk to End Alzheimer’s. The community‑focused event not only raised funds for research but also served as a rallying point for a pending federal bill that could dramatically improve early diagnosis of the disease.
Local effort fuels national legislation
Shannon Trest, manager of Walk to End Alzheimer’s Texarkana, explained the walk’s dual purpose. “It’s the biomarker test, which will test for dementia and Alzheimer’s and what we are trying to do is get legislation passed where Medicare will pay for that blood test,” she said. “I think it’s just critical that we get that legislation passed.”
The legislation in question is the Alzheimer’s Screening and Prevention Act, currently under review by Congress. If enacted, the bill would expand Medicare benefits to cover the cost of a newly‑developed blood test that can identify Alzheimer’s disease before symptoms appear. The coverage would take effect on Jan. 1, 2028, giving seniors and their families a valuable tool for early intervention.
Why early detection matters
Scientists have recently validated a blood‑based biomarker that can detect the protein plaques associated with Alzheimer’s years before cognitive decline becomes evident. Early detection opens the door to lifestyle changes, clinical trials, and emerging therapies that work best when started early. Advocates argue that Medicare coverage would remove a financial barrier for millions of older Americans who might otherwise forego testing.
“Early diagnosis is a game‑changer for families,” said Dr. Laura Martinez, a neurologist at the University of Texas Health Science Center who was not involved in the walk but has studied the test. “When we can identify the disease before it progresses, we can tailor treatment plans and give patients a better quality of life.”
Legislative outlook
The bill has garnered bipartisan support from lawmakers who see the test as a cost‑effective preventive measure. Proponents point to studies suggesting that early detection could reduce long‑term care costs by catching the disease before expensive interventions become necessary.
Critics, however, caution that broader Medicare coverage could increase short‑term spending and call for more data on the test’s accuracy across diverse populations. The Alzheimer’s Association, which sponsors the walk, acknowledges the need for continued research but maintains that the test’s performance meets rigorous standards.
How to support the cause
Community members who wish to back the legislation can visit the Alzheimer’s Impact Movement or the Alzheimer’s Association website to sign the petition for the ASAP Act. The walk’s organizers hope that the visible local turnout will signal to lawmakers that constituents across the nation, including Texarkana, are eager for federal action.
As the walk concluded, participants carried banners reading “Hope Starts with Early Detection” and “Medicare Should Cover the Test.” Their message underscores a growing national conversation about how to protect seniors, support families, and invest in medical innovation.
Original reporting: KTBS 3 (Shreveport) — read the source article.
